Array reports lead-in Phase III data for binimetinib and encorafenib in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) reported data from the safety lead-in portion of the Phase III BEACON CRC trial showing that binimetinib (MEK162) plus encorafenib (LGX818) and Erbitux cetuximab led to a confirmed overall response rate (ORR) of 41%, including 1 complete response, in 29 evaluable BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients who progressed after 1 or 2 prior regimens. In BRAF V600E-mutant mCRC patients who received only 1 prior therapy, the triplet combination led to an ORR of 59%. Array said the triplet combination was generally well tolerated. At the time of analysis, 76% of patients remained on treatment after a median treatment duration of 5.6 months. Data were presented at the European Society for Medical Oncology meeting in Madrid.

Array is now enrolling patients in the randomized portion of BEACON CRC, which will evaluate encorafenib plus Erbitux with or without binimetinib compared to Erbitux plus an irinotecan-based therapy. The trial will enroll about 645 patients total...